81 related articles for article (PubMed ID: 19606951)
1. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia.
Bouwmans C; Janssen J; Huijgens P; Uyl-de Groot C
J Med Econ; 2009 Jun; 12(2):164-9. PubMed ID: 19606951
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of haematological adverse effects in cancer patients: a systematic review.
Liou SY; Stephens JM; Carpiuc KT; Feng W; Botteman MF; Hay JW
Clin Drug Investig; 2007; 27(6):381-96. PubMed ID: 17506589
[TBL] [Abstract][Full Text] [Related]
4. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant outcome in chronic myeloid leukaemia.
Raza S; Ullah K; Ahmed P; Khan B; Kamal MK
J Coll Physicians Surg Pak; 2008 Oct; 18(10):615-9. PubMed ID: 18940118
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
9. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
Pavlu J; Andreasson C; Chuah C; Kaeda J; Goldman JM; Apperley JF; Marin D
Br J Haematol; 2007 Jun; 137(5):423-8. PubMed ID: 17428238
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of 54 chronic myelogenous leukemia with Gleevec].
Jiang H; Chen SS; Jiang B; Jiang Q; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2003 Jun; 24(6):281-5. PubMed ID: 12859861
[TBL] [Abstract][Full Text] [Related]
14. Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers.
Löfström B; Backlin C; Sundström C; Hellström-Lindberg E; Ekbom A; Lundberg IE
Rheumatology (Oxford); 2009 Oct; 48(10):1222-6. PubMed ID: 19608725
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Bee PC; Gan GG; Teh A; Haris AR
Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
[TBL] [Abstract][Full Text] [Related]
16. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
[TBL] [Abstract][Full Text] [Related]
17. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia.
Adler R; Viehmann S; Kuhlisch E; Martiniak Y; Röttgers S; Harbott J; Suttorp M
Eur J Haematol; 2009 Feb; 82(2):112-8. PubMed ID: 19067742
[TBL] [Abstract][Full Text] [Related]
18. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathologic features of chronic myeloid leukemia and risk stratification according to Sokal score.
Syed NN; Usman M; Khaliq G; Adil SN; Khurshid M
J Coll Physicians Surg Pak; 2006 May; 16(5):336-9. PubMed ID: 16756777
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
